| 367 |
ACUITY: One Year Outcome of ACUITY Trial |
Roxana Mehran |
May. 25. 07 |
| 366 |
ZOMAXX I: A Prospective, Multicenter, Randomized Trial of Zotarolimus-Eluting and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease: 9-Month Clinical and Angiographic Results |
Bernard R. Chevalier |
May. 25. 07 |
| 365 |
SPIRIT-III: Clinical, Angiographic and IVUS Results from the Pivotal United States Randomized SPIRIT-III Trial of the Xience V Everolimus Eluting Coronary Stent System in Patients With Coronary Artery Disease |
Gregg W. Stone |
May. 25. 07 |
| 364 |
Drug-Eluting Stent Restenosis: First Large, Multicenter Prospective Report of Treatment Strategies and Clinical Outcomes in the US From the Strategic Transcatheter Evaluation of New Therapies (STENT) Group |
Charles A. Simonton |
May. 25. 07 |
| 363 |
DECLARE-Diabetes: Drug Eluting Stent Followed by Cilostazol Treatment Reduces Late Restenosis in Patient with Diabetes Mellitus |
Seong-Wook Park |
May. 25. 07 |
| 362 |
ACUITY PCI: A Prospective Trial of Patients With Acute Coronary Syndromes Undergoing PCI After Randomization to Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibitors: 30-Day Clinical and Angiographic Core Laboratory Results |
Gregg W. Stone |
May. 25. 07 |
| 361 |
TAXUS Real-World Experience from ARRIVE Registry |
Alan C. Yeung |
May. 25. 07 |
| 360 |
The Problem Is Exaggerated: Data From "Real-World" Registries |
Antonio Colombo |
May. 18. 07 |
| 359 |
SFA Stenting and the Promise of DSA in the Peripheral Circulation |
John R. Laird |
May. 18. 07 |
| 358 |
Future Perspectives in Peripheral Intervention |
Michael R. Jaff |
May. 18. 07 |
